Nuformix PLC Director/PDMR Shareholding (9789X)

TIDMNFX

RNS Number : 9789X

Nuformix PLC

10 January 2022

10 January 2022

Nuformix plc

("Nuformix" or the "the Company")

Director/PDMR Shareholding

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that today the Company received notice that Dr Alastair Riddell purchased 400,000 ordinary shares of 0.1 pence each ("Ordinary Shares") at a price of 1.175 pence per share on 10 January 2022.

- Ends -

 
 Nuformix plc                                                    via Walbrook 
 Dr Alastair Riddell, Executive 
  Chairman 
 
 
 
   Allenby Capital Limited                               [phone] 
 Nick Athanas / George Payne (Corporate 
  Finance) 
 Stefano Aquilino / Matt Butlin (Sales 
  and Corporate Broking) 
 
 
   Walbrook PR                                 [e-mail] or +44 
                                                              (0)20 7933 8780 
 Anna Dunphy / Phillip Marriage                    Tel: [phone] / 
                                                          [phone] 
 
 

Enquiries:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                          Dr Alastair Riddell 
     ----------------------------  ------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------- 
 a)   Position/status               PDMR - Executive Chairman 
     ----------------------------  ------------------------------------- 
 b)   Initial notification          Initial notification 
       /Amendment 
     ----------------------------  ------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                          Nuformix plc 
     ----------------------------  ------------------------------------- 
 b)   LEI                           2138003XG3H3I2J3BJ24 
     ----------------------------  ------------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of the            Ordinary Shares of nominal value 
       financial instrument,         0.1 pence each 
       type of instrument 
 
       Identification code           GB00BYW79Y38 
     ----------------------------  ------------------------------------- 
 b)   Nature of the transaction     Purchase of Ordinary Shares 
     ----------------------------  ------------------------------------- 
 c)   Price(s) and volume(s)          Price(s)   Volume(s) 
                                       1.175p     400,000 
                                                 ---------- 
     ----------------------------  ------------------------------------- 
 d)   Aggregated information 
 
       - Aggregated volume            400,000 
 
       - Price                        1.175p 
 
       - Total                        GBP4,700.00 
     ----------------------------  ------------------------------------- 
 e)   Date of the transaction       10 January 2022 
     ----------------------------  ------------------------------------- 
 f)   Place of the transaction      London Stock Exchange, Main Market 
     ----------------------------  ------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGPUUPGUPPGQU

(END) Dow Jones Newswires

January 10, 2022 11:23 ET (16:23 GMT)